Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Shuttle Pharmaceuticals (SHPH) stock has reached a new 52-week low, trading at $0.57, as the company faces a challenging market environment. According to InvestingPro data, the company’s financial health score stands at 0.98 (WEAK), with concerning metrics including a low current ratio of 0.22 and negative EBITDA of -$7.2M. This latest price point reflects a significant downturn from the previous year, with the stock experiencing a substantial 1-year change of -81.1%. With a market capitalization of just $2.21M and return on equity at -328%, investors are closely monitoring SHPH as it navigates through the current economic conditions that have heavily impacted its market valuation. The 52-week low serves as a critical indicator for the company’s performance and investor sentiment over the past year. InvestingPro analysis reveals 11 additional warning signs that subscribers can access to make more informed investment decisions.
In other recent news, Shuttle Pharmaceuticals Holdings, Inc. reported significant progress in its Phase 2 clinical trial for Ropidoxuridine, a treatment aimed at enhancing radiation therapy for glioblastoma patients. The company announced that 40% of the initial randomized portion of the trial has been completed, with 16 out of the planned 40 patients enrolled. This trial is being conducted at several prominent cancer centers, including Georgetown University Medical (TASE:BLWV) Center and Miami Cancer Institute. Shuttle Pharma also expanded the trial by amending its agreement with Theradex Systems, Inc., increasing the number of sites from four to six and adjusting the budget to accommodate additional site monitoring.
Additionally, the company is working on developing a ligand for prostate-specific membrane antigen (PSMA) in collaboration with the University of California, San Francisco, which could serve both diagnostic and therapeutic purposes. Shuttle Pharma has recently launched a new corporate website to highlight its focus on cancer therapeutics and diagnostics. The company has received Orphan Drug Designation from the FDA for Ropidoxuridine, emphasizing its commitment to improving cancer treatment outcomes. Shuttle Pharma aims to complete the trial enrollment within the next year and continues to develop diagnostic tools for prostate cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.